Yoshiharu Uno
Research Subjects
Yoshiharu Uno has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Akihiro Munakata
First Department of Internal Medicine, the First Department of Surgery, and Central Pathology, Hirosaki University School of Medicine, Hirosaki, Japan
1 shared publicationDaisuke Nishiya
First Department of Internal Medicine, the First Department of Surgery, and Central Pathology, Hirosaki University School of Medicine, Hirosaki, Japan
1 shared publicationHiroshi Saito
First Department of Internal Medicine, the First Department of Surgery, and Central Pathology, Hirosaki University School of Medicine, Hirosaki, Japan
1 shared publicationJennifer C van Velkinburgh
Yoshiharu Uno, Office Uno Column (Medical Science Publisher), Onoe-Cho, Hyogo 675-0025, Japan
1 shared publicationRyo Yamagata
First Department of Internal Medicine, the First Department of Surgery, and Central Pathology, Hirosaki University School of Medicine, Hirosaki, Japan
1 shared publication- Shinsaku Fukuda
Department of Gastroenterology and Hematology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan
1 shared publication
Latest Publications
- 1 February 2022
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 37 (5) , 954
Paradigm shift in FODMAP theory
- 1 February 2022
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 37 (5) , 954
Paradigm shift in FODMAP theory
- 1 October 2020
- Published by Elsevier in Gastroenterology
- Vol. 159 (4) , 1622-1623
Why Does SARS-CoV-2 Invade the Gastrointestinal Epithelium?
- 1 October 2020
- Published by Elsevier in Gastroenterology
- Vol. 159 (4) , 1622-1623
Why Does SARS-CoV-2 Invade the Gastrointestinal Epithelium?
- 1 July 2020
- Published by Elsevier in Gastroenterology
- Vol. 159 (1) , 399
Why a Low FODMAP Diet Was Ineffective for IBS Symptoms in Quiescent Crohn's Disease
- 1 July 2020
- Published by Elsevier in Gastroenterology
- Vol. 159 (1) , 399
Why a Low FODMAP Diet Was Ineffective for IBS Symptoms in Quiescent Crohn's Disease
- Open Access
- 1 July 2020
- Published by Elsevier in Gastroenterology
- Vol. 159 (1) , 404-405
Risk Factors and Incidence of Gastric Cancer after Eradication of Helicobacter pylori
- 1 July 2020
- Published by Elsevier in Gastroenterology
- Vol. 159 (1) , 404-405
Open AccessRisk Factors and Incidence of Gastric Cancer after Eradication of Helicobacter pylori
- 29 April 2020
- Published by Springer Nature in Internal and Emergency Medicine
- Vol. 15 (8) , 1577-1578
Camostat mesilate therapy for COVID-19
- 29 April 2020
- Published by Springer Nature in Internal and Emergency Medicine
- Vol. 15 (8) , 1577-1578
Camostat mesilate therapy for COVID-19
- Open Access
- 27 February 2020
- Published by Wiley in Neurogastroenterology & Motility
- Vol. 32 (3) , e13772
GERD by colonic fermentation
- 27 February 2020
- Published by Wiley in Neurogastroenterology & Motility
- Vol. 32 (3) , e13772
Open AccessGERD by colonic fermentation
- 1 November 2019
- Published by Elsevier in Medical Hypotheses
- Vol. 132, 109324
Hypothesis: Mechanism of irritable bowel syndrome in inflammatory bowel disease
- 1 November 2019
- Published by Elsevier in Medical Hypotheses
- Vol. 132, 109324
Hypothesis: Mechanism of irritable bowel syndrome in inflammatory bowel disease
- 23 July 2019
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 114 (9) , 1553-1554
Influence of Dietary Fiber in Low FODMAP Diet for Irritable Bowel Syndrome
- 23 July 2019
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 114 (9) , 1553-1554
Influence of Dietary Fiber in Low FODMAP Diet for Irritable Bowel Syndrome
- Open Access
- 23 May 2019
- Published by Wiley in Cancer Medicine
- Vol. 8 (8) , 3992-4000
Prevention of gastric cancer by Helicobacter pylori eradication: A review from Japan
Japan introduced a Helicobacter pylori eradication therapy strategy in 2013, with the aim of decreasing the number of gastric cancer‐related death, the number of new cases of gastric cancer, and associated medical costs. Five years have passed since then, but no reduction in the annual number of gastric cancer has been observed. In addition, it was suggested that the number of deaths due to gastric cancer could be reduced to 30,000 a year by 2020, but the annual death toll in 2017 remained at more than 45,000. Based on the above evidence, it was examined whether it was possible to reach the target value based on the data from the last 5 years. The number of deaths per year in 2020 is predicted to be more than 40,000, which is clearly different from the target value. Logically, the effect of the strategy might appear by 2023. However, there is a possibility that the risk of gastric cancer may increase in some populations due to the influence of proton pump inhibitors and dysbiosis in the gastric microbiome. To solve these problems, combined therapy with PPIs and aspirin for patients after H pylori eradication should be considered.
- 23 May 2019
- Published by Wiley in Cancer Medicine
- Vol. 8 (8) , 3992-4000
Open AccessPrevention of gastric cancer by Helicobacter pylori eradication: A review from Japan
Japan introduced a Helicobacter pylori eradication therapy strategy in 2013, with the aim of decreasing the number of gastric cancer‐related death, the number of new cases of gastric cancer, and associated medical costs. Five years have passed since then, but no reduction in the annual number of gastric cancer has been observed. In addition, it was suggested that the number of deaths due to gastric cancer could be reduced to 30,000 a year by 2020, but the annual death toll in 2017 remained at more than 45,000. Based on the above evidence, it was examined whether it was possible to reach the target value based on the data from the last 5 years. The number of deaths per year in 2020 is predicted to be more than 40,000, which is clearly different from the target value. Logically, the effect of the strategy might appear by 2023. However, there is a possibility that the risk of gastric cancer may increase in some populations due to the influence of proton pump inhibitors and dysbiosis in the gastric microbiome. To solve these problems, combined therapy with PPIs and aspirin for patients after H pylori eradication should be considered.
- Open Access
- 1 May 2018
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 12 (3) , 367-368
"Latent Gastric Cancer" after Eradicating Helicobacter pylori
Yoshiharu Uno. Gut and Liver 2018;12:367-8. https://doi.org/10.5009/gnl17463
- 1 May 2018
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 12 (3) , 367-368
Open Access"Latent Gastric Cancer" after Eradicating Helicobacter pylori
Yoshiharu Uno. Gut and Liver 2018;12:367-8. https://doi.org/10.5009/gnl17463